Bronchiolitis Obliterans Overview

Save information for later
Sign Up

Learn About Bronchiolitis Obliterans

What is the definition of Bronchiolitis Obliterans?
Bronchiolitis obliterans is an inflammatory condition that affects the lung's tiniest airways, the bronchioles. In affected people, the bronchioles may become damaged and inflamed leading to extensive scarring that blocks the airways. Symptoms of the condition include a dry cough; shortness of breath; and/or fatigue and wheezing in the absence of a cold or asthma. Many different chemicals (such as nitrogen oxides, ammonia, welding fumes or food flavoring fumes) and respiratory infections can cause lung injury that leads to Bronchiolitis obliterans. It can also be associated with rheumatoid arthritis and graft-versus-host disease following a lung or hematopoietic cell transplantation. Another similarly named disease, Bronchiolitis obliterans organizing pneumonia, is a different disease.
What are the alternative names for Bronchiolitis Obliterans?
  • Bronchiolitis obliterans
  • Obliterative bronchiolitis
Who are the top Bronchiolitis Obliterans Local Doctors?
Geert M. Verleden
Elite in Bronchiolitis Obliterans
Geert M. Verleden
Elite in Bronchiolitis Obliterans
Geert M. Verleden
Edegem, VLG, BE 

Geert Verleden practices in Edegem, Belgium. Verleden is rated as an Elite expert by MediFind in the treatment of Bronchiolitis Obliterans. Their top areas of expertise are Bronchiolitis Obliterans, Bronchitis, Hypersensitivity Pneumonitis, Lung Transplant, and Heart Transplant.

Sandra J. Hodge
Elite in Bronchiolitis Obliterans
Sandra J. Hodge
Elite in Bronchiolitis Obliterans
Sandra J. Hodge
4 North Terrace, 
Adelaide, SA, AU 

Sandra Hodge practices in Adelaide, Australia. Ms. Hodge is rated as an Elite expert by MediFind in the treatment of Bronchiolitis Obliterans. Her top areas of expertise are Bronchiolitis Obliterans, Chronic Obstructive Pulmonary Disease (COPD), Bronchitis, Lung Transplant, and Percutaneous Coronary Intervention (PCI).

 
 
 
 
Learn about our expert tiers
Learn More
Tobias Welte
Elite in Bronchiolitis Obliterans
Tobias Welte
Elite in Bronchiolitis Obliterans
Tobias Welte
Carl Neuberg Str. 1, 
Hannover, NI, DE 

Tobias Welte practices in Hannover, Germany. Mr. Welte is rated as an Elite expert by MediFind in the treatment of Bronchiolitis Obliterans. His top areas of expertise are Pneumonia, Chronic Obstructive Pulmonary Disease (COPD), Bronchiectasis, Lung Transplant, and Endoscopy.

View All Doctors
What are the latest Bronchiolitis Obliterans Clinical Trials?
Ruxolitinib for Early Lung Dysfunction After HSCT: a Phase II Study
Ruxolitinib for Early Lung Dysfunction After HSCT: a Phase II Study
Who is this study for: Patients with early lung dysfunction after HSCT
Enrollment Status: Recruiting
Publish Date: December 16, 2025
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2

Summary: Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy, and lung injury affects as many as 25% of children receiving HSCT. Improved transplant techniques and major improvements in survival mean that HSCT is being more widely used, and more mismatched grafts are being used. Bronchiolitis obliterans (BO) is a major limitation of pediatric HSCT success as BO is commonly diagnosed...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation (HSCT)- a Multicentre Phase II Trial
Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation (HSCT)- a Multicentre Phase II Trial
Who is this study for: Patients with Bronchiolitis Obliterans
Enrollment Status: Recruiting
Publish Date: December 15, 2025
Intervention Type: Drug
Study Drug: Nintedanib
Study Phase: Phase 2

Summary: This study investigates the safety and tolerability of Nintedanib in patients with bronchiolitis obliterans syndrome (BOS) following allogeneic hematopoietic cell transplantation. All study patients with BOS will be treated with the study drug Nintedanib (300 mg/day) as an add-on therapy to their basic immunosuppressive treatment over a 12-months treatment period.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center